A new day in preventing meningococcal disease: Sizing up the available vaccines

Article

The new conjugate vaccine MCV4 promises longer duration of immunity and, perhaps, greater clinical efficacy than the polysaccharide vaccine MPSV4. Questions remain about booster doses, vaccinating young children, and safety.

Recent Videos
Russell Libby, MD, FAAP
Greg Forlenza, MD
Lawrence Eichenfield, MD
Nathan Kuppermann, MD, MPH
COVID-19 Roundtable: Considering off label therapies
Greg Forlenza, MD
Greg Forlenza, MD
COVID-19 Therapy Roundtable: Focusing on Inpatient Care | Image credit: Production Perig
Image credit: Production Perig
© 2025 MJH Life Sciences

All rights reserved.